FLURBIPROFEN

Flurbiprofen Adverse Events Reported to the FDA Over Time

How are Flurbiprofen adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Flurbiprofen, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Flurbiprofen is flagged as the suspect drug causing the adverse event.

Most Common Flurbiprofen Adverse Events Reported to the FDA

What are the most common Flurbiprofen adverse events reported to the FDA?

Toxic Anterior Segment Syndrome	76 (8.64%)
Drug Rash With Eosinophilia And Sys...	38 (4.32%)
Abnormal Dreams	18 (2.05%)
Inflammation	15 (1.7%)
Iridocyclitis	13 (1.48%)
Cerebral Haematoma	12 (1.36%)
Eye Disorder	12 (1.36%)
Vomiting	12 (1.36%)
Drug Ineffective	10 (1.14%)
Dyspnoea	9 (1.02%)
Nausea	9 (1.02%)
	Show More
Pyrexia	9 (1.02%)
Rash	9 (1.02%)
Renal Failure Acute	9 (1.02%)
Alanine Aminotransferase Increased	8 (.91%)
Anaemia	8 (.91%)
Aspartate Aminotransferase Increase...	8 (.91%)
Drug Exposure During Pregnancy	8 (.91%)
Asthenia	6 (.68%)
Colitis Collagenous	6 (.68%)
Endophthalmitis	6 (.68%)
Lymphocyte Stimulation Test Positiv...	6 (.68%)
Mydriasis	6 (.68%)
Uveitis	6 (.68%)
Vitritis	6 (.68%)
Blood Lactate Dehydrogenase Increas...	5 (.57%)
Caesarean Section	5 (.57%)
Gamma-glutamyltransferase Increased	5 (.57%)
General Physical Health Deteriorati...	5 (.57%)
Malaise	5 (.57%)
Oxygen Saturation Decreased	5 (.57%)
Platelet Count Decreased	5 (.57%)
Pupils Unequal	5 (.57%)
Blood Creatinine Increased	4 (.45%)
Cerebral Haemorrhage	4 (.45%)
Cerebrovascular Accident	4 (.45%)
Coagulopathy	4 (.45%)
Dizziness	4 (.45%)
Duodenal Ulcer Haemorrhage	4 (.45%)
Eye Irritation	4 (.45%)
Gastrointestinal Haemorrhage	4 (.45%)
Haematocrit Decreased	4 (.45%)
Haemoglobin Decreased	4 (.45%)
Headache	4 (.45%)
Hepatic Failure	4 (.45%)
Hypersensitivity	4 (.45%)
Hypoalbuminaemia	4 (.45%)
Hypotension	4 (.45%)
Incision Site Haemorrhage	4 (.45%)
Interstitial Lung Disease	4 (.45%)
Loss Of Consciousness	4 (.45%)
Pancreatitis	4 (.45%)
Pneumonia	4 (.45%)
Product Quality Issue	4 (.45%)
Shock	4 (.45%)
Spinal Compression Fracture	4 (.45%)
Toxic Epidermal Necrolysis	4 (.45%)
Visual Acuity Reduced	4 (.45%)
Abdominal Pain Upper	3 (.34%)
Agranulocytosis	3 (.34%)
Airway Peak Pressure Increased	3 (.34%)
Anal Haemorrhage	3 (.34%)
Anorexia	3 (.34%)
Blindness	3 (.34%)
Cytolytic Hepatitis	3 (.34%)
Disease Recurrence	3 (.34%)
Drug Interaction	3 (.34%)
Eye Pain	3 (.34%)
Generalised Erythema	3 (.34%)
Heart Rate Increased	3 (.34%)
Helicobacter Pylori Identification ...	3 (.34%)
Hepatic Function Abnormal	3 (.34%)
Mechanical Ventilation Complication	3 (.34%)
Medication Error	3 (.34%)
Myodesopsia	3 (.34%)
Oedema	3 (.34%)
Pain	3 (.34%)
Peritonitis	3 (.34%)
Post Procedural Complication	3 (.34%)
Renal Failure	3 (.34%)
Renal Impairment	3 (.34%)
Rhabdomyolysis	3 (.34%)
Scintillating Scotoma	3 (.34%)
Somnolence	3 (.34%)
Tremor	3 (.34%)
Urticaria	3 (.34%)
Weight Decreased	3 (.34%)
White Blood Cell Count Increased	3 (.34%)
Abdominal Discomfort	2 (.23%)
Acute Febrile Neutrophilic Dermatos...	2 (.23%)
Antibody Test Positive	2 (.23%)
Apnoea	2 (.23%)
Arthritis	2 (.23%)
Bleeding Time Prolonged	2 (.23%)
Blindness Transient	2 (.23%)
Blood Albumin Decreased	2 (.23%)
Blood Alkaline Phosphatase Increase...	2 (.23%)
Blood Bilirubin Increased	2 (.23%)
Blood Glucose Increased	2 (.23%)
Bradycardia	2 (.23%)
Cataract Operation Complication	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Flurbiprofen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Flurbiprofen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Flurbiprofen

What are the most common Flurbiprofen adverse events reported to the FDA?

Procedural And Device Related Injur...	91 (10.34%)
Epidermal And Dermal Conditions	71 (8.07%)
Ocular Infections, Irritations And ...	37 (4.2%)
Hematology Investigations	33 (3.75%)
Gastrointestinal Signs	28 (3.18%)
Hepatobiliary	23 (2.61%)
Central Nervous System Vascular	21 (2.39%)
Eye	21 (2.39%)
Respiratory	19 (2.16%)
Sleep Disorders	19 (2.16%)
Hepatic And Hepatobiliary	17 (1.93%)
	Show More
Infections - Pathogen Unspecified	17 (1.93%)
Neurological	17 (1.93%)
Therapeutic And Nontherapeutic Effe...	17 (1.93%)
Renal Disorders	16 (1.82%)
Body Temperature Conditions	15 (1.7%)
Vision	15 (1.7%)
Ocular Neuromuscular	13 (1.48%)
Gastrointestinal Hemorrhages	12 (1.36%)
Gastrointestinal Inflammatory Condi...	12 (1.36%)
Gastrointestinal Ulceration And Per...	12 (1.36%)
Chemical Injury And Poisoning	11 (1.25%)
Anemias Nonhemolytic And Marrow Dep...	10 (1.14%)
Medication Errors	10 (1.14%)
Decreased And Nonspecific Blood Pre...	9 (1.02%)
Allergic Conditions	8 (.91%)
Anterior Eye Structural Change, Dep...	8 (.91%)
Metabolic, Nutritional And Blood Ga...	8 (.91%)
Enzyme	7 (.8%)
Microbiology And Serology	7 (.8%)
Lower Respiratory Tract Disorders	6 (.68%)
Appetite And General Nutritional	5 (.57%)
Bone And Joint Injuries	5 (.57%)
Cardiac Arrhythmias	5 (.57%)
Exocrine Pancreas Conditions	5 (.57%)
Muscle	5 (.57%)
Obstetric And Gynecological Therape...	5 (.57%)
Ocular Structural Change, Deposit A...	5 (.57%)
Product Quality Issues	5 (.57%)
Renal And Urinary Tract Investigati...	5 (.57%)
Angiedema And Urticaria	4 (.45%)
Bacterial Infectious	4 (.45%)
Cardiac And Vascular Investigations	4 (.45%)
Coagulopathies And Bleeding Diathes...	4 (.45%)
Headaches	4 (.45%)
Musculoskeletal And Connective Tiss...	4 (.45%)
Physical Examination Topics	4 (.45%)
Protein And Amino Acid Metabolism	4 (.45%)
Seizures	4 (.45%)
White Blood Cell	4 (.45%)
Administration Site Reactions	3 (.34%)
Cardiac And Vascular Disorders Cong...	3 (.34%)
Cardiac Disorder Signs	3 (.34%)
Electrolyte And Fluid Balance Condi...	3 (.34%)
Gastrointestinal Motility And Defec...	3 (.34%)
Joint	3 (.34%)
Mental Impairment	3 (.34%)
Movement Disorders	3 (.34%)
Musculoskeletal And Connective Tiss...	3 (.34%)
Neonatal Respiratory	3 (.34%)
Oral Soft Tissue Conditions	3 (.34%)
Peritoneal And Retroperitoneal Cond...	3 (.34%)
Protein And Chemistry Analyses	3 (.34%)
Respiratory And Pulmonary Investiga...	3 (.34%)
Urinary Tract Signs	3 (.34%)
Abortions And Stillbirth	2 (.23%)
Bone Disorders	2 (.23%)
Bronchial Disorders	2 (.23%)
Coronary Artery	2 (.23%)
Deliria	2 (.23%)
Fetal And Neonatal	2 (.23%)
Gastrointestinal Stenosis And Obstr...	2 (.23%)
Gastrointestinal Tract Disorders Co...	2 (.23%)
Immunology And Allergy	2 (.23%)
Lifestyle Issues	2 (.23%)
Metastases	2 (.23%)
Nervous System, Skull And Spine The...	2 (.23%)
Neurological Disorders Congenital	2 (.23%)
Neuromuscular	2 (.23%)
Ocular Hemorrhages And Vascular	2 (.23%)
Pregnancy, Labour, Delivery And Pos...	2 (.23%)
Therapeutic Procedures And Supporti...	2 (.23%)
Tongue Conditions	2 (.23%)
Anxiety Disorders	1 (.11%)
Arteriosclerosis, Stenosis, Vascula...	1 (.11%)
Aural	1 (.11%)
Congenital And Hereditary	1 (.11%)
Connective Tissue Disorders	1 (.11%)
Cranial Nerve Disorders	1 (.11%)
Ear And Labyrinthine Disorders Cong...	1 (.11%)
Eye Disorders Congenital	1 (.11%)
Eye Therapeutic Procedures	1 (.11%)
Fetal Complications	1 (.11%)
Gastrointestinal Neoplasms Malignan...	1 (.11%)
Hearing	1 (.11%)
Heart Failures	1 (.11%)
Hematological And Lymphoid Tissue T...	1 (.11%)
Immune	1 (.11%)
Increased Intracranial Pressure And...	1 (.11%)
Injuries	1 (.11%)
Injuries By Physical Agents	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Flurbiprofen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Flurbiprofen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.